WO2000050618A1 - Vecteur viral - Google Patents
Vecteur viral Download PDFInfo
- Publication number
- WO2000050618A1 WO2000050618A1 PCT/JP2000/001069 JP0001069W WO0050618A1 WO 2000050618 A1 WO2000050618 A1 WO 2000050618A1 JP 0001069 W JP0001069 W JP 0001069W WO 0050618 A1 WO0050618 A1 WO 0050618A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- virus
- gene
- msh
- seq
- vector according
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/854—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002365026A CA2365026A1 (en) | 1999-02-24 | 2000-02-24 | Virus vector |
AU26914/00A AU2691400A (en) | 1999-02-24 | 2000-02-24 | Virus vector |
EP00905319A EP1156118A4 (en) | 1999-02-24 | 2000-02-24 | VIRAL VECTOR |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11093263A JP2000279178A (ja) | 1999-02-24 | 1999-02-24 | ウイルスベクター |
JP11/93263 | 1999-02-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000050618A1 true WO2000050618A1 (fr) | 2000-08-31 |
Family
ID=14077606
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2000/001069 WO2000050618A1 (fr) | 1999-02-24 | 2000-02-24 | Vecteur viral |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1156118A4 (ja) |
JP (1) | JP2000279178A (ja) |
AU (1) | AU2691400A (ja) |
CA (1) | CA2365026A1 (ja) |
WO (1) | WO2000050618A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001037866A1 (en) * | 1999-11-25 | 2001-05-31 | The University Of Newcastle Research Associates Limited | A method of treating a malignancy in a subject and a pharmaceutical composition for use in same |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4186978A1 (en) | 2007-12-27 | 2023-05-31 | Universität Zürich | Replication-defective arenavirus vectors |
ES2751423T3 (es) | 2013-03-15 | 2020-03-31 | Univ Geneve | Vacunas antimicobacterianas |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998044121A1 (fr) * | 1997-04-02 | 1998-10-08 | Transgene S.A. | Fibre adenovirale modifiee et adenovirus cibles |
WO1998054346A1 (en) * | 1997-05-28 | 1998-12-03 | Genvec, Inc. | Alternatively targeted adenovirus |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0633943A4 (en) * | 1992-04-03 | 1997-05-02 | Alexander T Young | GENTHERAPY USING TARGETED VIRAL VECTORS. |
JPH08504091A (ja) * | 1992-09-22 | 1996-05-07 | メディカル・リサーチ・カウンシル | 外部表面に非ウィルス性ポリペプチドを提示する組換えウィルス |
GB9223084D0 (en) * | 1992-11-04 | 1992-12-16 | Imp Cancer Res Tech | Compounds to target cells |
US6312699B1 (en) * | 1994-03-28 | 2001-11-06 | Uab Research Foundation | Ligands added to adenovirus fiber |
US5846782A (en) * | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
US5994132A (en) * | 1996-10-23 | 1999-11-30 | University Of Michigan | Adenovirus vectors |
AU2662999A (en) * | 1998-02-09 | 1999-08-23 | Genzyme Corporation | Nucleic acid delivery vehicles |
US6649396B1 (en) * | 1999-02-05 | 2003-11-18 | Uab Research Foundation | Fiber receptor-independent system for the propagation of adenoviral vectors |
-
1999
- 1999-02-24 JP JP11093263A patent/JP2000279178A/ja active Pending
-
2000
- 2000-02-24 CA CA002365026A patent/CA2365026A1/en not_active Abandoned
- 2000-02-24 EP EP00905319A patent/EP1156118A4/en not_active Withdrawn
- 2000-02-24 WO PCT/JP2000/001069 patent/WO2000050618A1/ja not_active Application Discontinuation
- 2000-02-24 AU AU26914/00A patent/AU2691400A/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998044121A1 (fr) * | 1997-04-02 | 1998-10-08 | Transgene S.A. | Fibre adenovirale modifiee et adenovirus cibles |
WO1998054346A1 (en) * | 1997-05-28 | 1998-12-03 | Genvec, Inc. | Alternatively targeted adenovirus |
Non-Patent Citations (11)
Title |
---|
AN JIANG ET AL.: "Cell-type-specific gene transfer into human cells with retroviral vectors that display single-chain antibodies", JOURNAL OF VIROLOGY,, vol. 72, no. 12, 1998, pages 10148 - 10156, XP002927079 * |
IGOR DMITRIEV ET AL.: "An Adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a Coxsackievirus and Adenovirus receptor-independent cell entry mechanism", JOURNAL OF VIROLOGY,, vol. 72, no. 12, 1998, pages 9706 - 9713, XP002927078 * |
JADWIGA CHROBOCZEK ET AL.: "The sequence of Adenovirus fiber: similalities and differences between serotypes 2 and 5", VIROLOGY,, vol. 161, no. 2, 1987, pages 549 - 554, XP002927071 * |
NOBUSADA SHINOURA ET AL.: "Highly augmented cytopathic effect of a fiber-mutant E1B-defective Adenovirus for gene therapy of Gliomas", CANCER RESEARCH,, vol. 59, no. 14, July 1999 (1999-07-01), pages 3411 - 3416, XP002927072 * |
SATOSHI YAMAGUCHI ET AL.: "Enhancement of retrovirus-mediated gene transduction efficiency by transient ovcerexpression of the amphotropic receptor, GLVR-2", NUCLEIC ACIDS RESEARCH,, vol. 23, no. 11, 1995, pages 2080 - 2081, XP002927073 * |
See also references of EP1156118A4 * |
SYLVIE LAQUERRE ET AL.: "Recombinant herpes simplex virus type 1 engineered for targeted binding to erythropoietin receptor-bearing cells", JOURNAL OF VIROLOGY,, vol. 72, no. 12, 1998, pages 9683 - 9697, XP002927080 * |
THOMAS J. WICKHAM ET AL.: "Increased in vitro and in vivo gene transfer by Adenovirus vectors containing chimeric fiber proteins", JOURNAL OF VIROLOGY,, vol. 71, no. 11, 1997, pages 8221 - 8229, XP002927077 * |
WALTER SIEGRIST ET AL.: "Characterization of receptor for alpha-MSH on human melanoma cells", CANCER RESEARCH,, vol. 49, no. 22, 1989, pages 6352 - 6358, XP002927075 * |
WYSUN WONG ET AL.: "Binding and internalization of the melanocyte stimulating hormone receptor ligand(N6e,D-Phe) alpha-MSH in B16 melanoma cells", INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY,, vol. 28, no. 11, 1996, pages 1223 - 1232, XP002927074 * |
YOKO YOSHIDA ET AL.: "Generation of fiber-mutant recombinant Adenovirus for gene therapy of malignant glioma", HUMAN GENE THERAPY,, vol. 9, no. 17, 1998, pages 2503 - 2515, XP002927076 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001037866A1 (en) * | 1999-11-25 | 2001-05-31 | The University Of Newcastle Research Associates Limited | A method of treating a malignancy in a subject and a pharmaceutical composition for use in same |
US7361354B1 (en) | 1999-11-25 | 2008-04-22 | Viralytics Limited | Methods for treating malignancies expressing ICAM-1 using coxsackie a group viruses |
US8722036B2 (en) | 1999-11-25 | 2014-05-13 | Viralytics Limited | Methods for treating malignancies using coxsackieviruses |
Also Published As
Publication number | Publication date |
---|---|
AU2691400A (en) | 2000-09-14 |
JP2000279178A (ja) | 2000-10-10 |
CA2365026A1 (en) | 2000-08-31 |
EP1156118A1 (en) | 2001-11-21 |
EP1156118A4 (en) | 2002-09-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102628234B1 (ko) | 알부민-결합 모이어티를 포함하는 아데노바이러스 | |
JP4874247B2 (ja) | 腫瘍溶解性アデノウイルス組換え体、特に、腫瘍において免疫調節因子gm−csfを発現する組換え体の構築およびその利用 | |
ES2258265T3 (es) | Vectores de replicacion con especificidad tisular. | |
AU708870B2 (en) | Gene therapy using ovine adenoviral vectors | |
Kleinerman et al. | Application of a tumor suppressor (C-CAM1)-expressing recombinant adenovirus in androgen-independent human prostate cancer therapy: a preclinical study | |
ES2232574T3 (es) | Poxvirus con especialidad de infeccion dirigida. | |
US6824771B1 (en) | Infectivity-enhanced conditionally-replicative adenovirus and uses thereof | |
ES2210081T3 (es) | Utilizacion de los marcos de lectura de la region e4 para la mejora de la expresion de genes. | |
JPH11501219A (ja) | 細胞への遣伝子導入のためのベクターおよび方法 | |
AU699867B2 (en) | Recombinant adenoviruses for gene therapy in cancers | |
Loser et al. | Advances in the development of non-human viral DNA-vectors for gene delivery | |
JP2001505047A (ja) | 高キャパシティーアデノウイルスベクターの開発の促進に使用するためのパッケージング細胞系 | |
US9175309B2 (en) | Recombinant adenovirus with enhanced therapeutic effect and pharmaceutical composition comprising said recombinant adenovirus | |
EP3305904B1 (en) | Poxvirus-derived promoter, and vector comprising same | |
US20050036989A1 (en) | Subgroup B adenoviral vectors for treating disease | |
US20170065685A1 (en) | Serca2 therapeutic compositions and methods of use | |
JP2004500097A (ja) | Tcf応答性エレメント | |
US20230279429A1 (en) | Dna molecules producing custom designed replicating and non-replicating negative stranded rna viruses and uses there of | |
WO2000050618A1 (fr) | Vecteur viral | |
WO1999044423A1 (en) | Amplification of gene transfer and gene therapy by controlled replication | |
Hsieh et al. | New prospectives of prostate cancer gene therapy: molecular targets and animal models | |
JP2005336199A5 (ja) | ||
KR20230095830A (ko) | 면역 회피성 항종양 아데노바이러스 | |
JP2002330774A (ja) | 標的化感染特異性を有するポックスウイルス | |
Nazemi-Moghaddam | Optimization of adenoviral vectors for cancer suicide gene therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 601182 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref document number: 2365026 Country of ref document: CA Ref country code: CA Ref document number: 2365026 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09914151 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000905319 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000905319 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000905319 Country of ref document: EP |